ABSTRACT
multiprotein complex comprising a sensor protein, the adaptor protein ASC, and caspase-1 (5) . Inflammasome sensor protein appears in several forms and is a member of the NLR family, which includes NLRP1, NAIP/ NLRC4, NLRP3, and NLRP6, AIM2-like receptors, and the tripartite motif-containing family member pyrin (6) . NLRP3 and ASC interact through the pyrin-pyrin domain, and this interaction with ASC promotes the activation of caspase-1, which induces the release of proinflammatory cytokines such as IL-1b and IL-18 (5) . Generally, inflammasome activation appears to be a key regulator of the responses to vaccines and stimulation of the immune system by pathogens (7) .
Previous reports using KO mice that were deficient in one of the inflammasome component proteins, such as NLRP3, have shown that the inflammasome has an important role in vaccine function (5) (6) (7) (8) (9) . These studies have shown that inflammasome component-KO mice did not show innate or adaptive immunity because they did not recruit leukocytes or produce IL-1b. In addition, these KO mice produce a lower IgG 1 titer compared with WT mice.
Generally, immunization with protein only produces low immunogenicity and stability (4) . To increase protein vaccine efficacy, many variations have been tried, such as increasing the amount of antigen or using chimeric booster immunization (10) . Currently, the most widely used method is the inclusion of an adjuvant in a vaccine (11) . Aluminum adjuvant, called simply 'alum', is an adjuvant commonly used in various human and animal vaccines (11) . However, it is not clear how alum triggers the immune response when included in a vaccine (12) . Some studies have reported that alum allows the antigen to be released slowly from the antigen-alum complex, which provides a better uptake by APC (13, 14) . Alum also induces a proinflammatory response, as shown by the secretion of IL-1b as a result of stimulation of NLRP3 in inflammasome complexes (9) , and it may contribute to the recruitment and stimulation of APC (13, 14) . Although the roles of alum and inflammasomes in the proinflammatory process are understood, it is not clear whether or how the inflammasome component, ASC, plays a role in the immune response to a vaccine formulated with or without alum.
In the present study, we used two types of vaccine: a cell culture-produced and inactivated influenza vaccine formulated without alum, and a recombinant HPV vaccine, which is a virus-like particle, formulated with alum. We immunized ASC-KO (ASC À/À ) mice to investigate the role of ASC in vaccine efficacy. Our data showed that ASC plays a crucial role in vaccine efficacy and defense against infection. We also found that the protein vaccine formulated with alum could overcome the deficiency in ASC À/À mice. Our findings suggest that alum may work through a bypass mechanism possibly involving inflammasome activation.
MATERIALS AND METHODS

Mice
C57BL/6J male and female mice were purchased at 10 weeks of age from Daehan Bio Link (Chungbuk, Korea). ASC-deficient (ASC À/À ) mice on a C57BL/6J background were kindly provided by Prof. Gabriel N uñez (University of Michigan) and group-housed within the animal facility. The male mice were used for influenza vaccination and the female mice were used for HPV vaccination. All mice were housed under specific pathogen-free conditions with a standard light cycle (12 hr light/dark). All animal procedures were approved by the Institutional Animal Care and Use Committee of Catholic University of Korea.
Vaccinations
The WT and ASC À/À mice were immunized twice with the influenza vaccine or three times with the HPV vaccine. The dose was 6 mg per mouse given i.m. at 2-week intervals. Inactivated influenza virus vaccine is a cell-based vaccine (Sky CellFlu pre-filled syringe vaccine; SK Chemical, Andong, South Korea), and the recombinant HPV vaccine is a virus-like particle recombinant vaccine made in an insect cell culture system (from SK Chemical). Spodoptera frugiperda Sf9 insect cells were obtained from the ATCC and maintained in Insect-XPRESS TM medium (Lonas, Basel, Switzerland). Full length L1 gene of HPV (types 6, 11, 16, and 18) was cloned into pBacPAK8 baculovirus transfer vector. HPV L1 protein was produced in Sf9 cells infected with recombinant baculovirus. L1 protein was purified using a combination of anion exchange and glucose affinity chromatography. Finally, L1 protein was formulated with aluminum adjuvant (alum) or without alum.
Challenge with influenza virus
Each mouse was infected with 5.5 Â 10 4 pfu influenza virus (A/H1N1/California/04/09) through an intranasal injection. Influenza viruses were provided by Professor Baik-Lin Seong (Yonsei University, South Korea).
Serum collection
Serum was collected from influenza vaccine-immunized mice at 2 and 4 weeks and from HPV vaccineimmunized mice at 2, 4, and 7 weeks after the first vaccination. The serum samples were collected from the facial vein using an 18-G needle. The samples were stored at À80°C until later use.
Indirect ELISA
To measure the concentrations of vaccine-specific antibodies in mouse serum, an indirect ELISA was carried out. 
Hemagglutination inhibition test
The HI titer was measured in serum from influenza vaccine-immunized mice as follows. Mouse serum samples were incubated overnight with a 3Â volume of receptor-destroying enzyme (Denka Seiken, Tokyo, Japan) at 37°C. The next day, the same volume of PBS was added, and the sample mixture was heat inactivated at 56°C for 30 min. The serum samples were incubated with a twofold serial dilution of the influenza virus at a HA concentration of 8/50 mL in the wells of a 96-well V-bottom plate (Corning) for 1 hr. The samples were incubated with the same volume of 1% chicken red blood cells at 4°C for 30 min. The results were evaluated and calculated as HI units.
Histology
Lung tissue obtained from influenza virus-infected mice was fixed in 10% neutral formalin (Sigma-Aldrich, St Louis, MO, USA), embedded in paraffin, and stained with hematoxylin and eosin (AbClon Company, Seoul, South Korea).
Plaque-reduction neutralization test for influenza virus
Serum samples from vaccinated mice were inactivated at 56°C for 30 min. The samples were serially diluted 2-10 times dilution and then incubated with 200 pfu influenza virus at 37°C for 1 hr. The samples were applied to monolayers of MDCK cells in 12-well plates (Corning) and incubated at 37°C for 1 hr. The inoculum was removed, the monolayer was overlaid with Dulbecco's modified Eagle's medium (DMEM; Hyclone, Logan, UT, USA) containing 0.001% (v/v) trypsin (Life Technologies, Gaithersburg, MD, USA) and 1% (w/v) agarose (Lonza, Basel, Switzerland), and the cells were incubated for 3 days at 37°C. The cells were then fixed with methanol-acetic acid (3:1; both from Duksan Pure Chemicals, Ansan, South Korea) and stained with crystal violet solution (Sigma-Aldrich).
Tetramer assay to measure CTL responses
For the tetramer assay, cell suspensions obtained from lung tissue were blocked with anti-mouse CD16/32 (BD Pharmingen, San Diego, CA, USA) and streptavidin (Invitrogen, Eugene, OR, USA). The cells were stained with FITC-conjugated anti-mouse CD44 (clone IM7; BioLegend, San Diego, CA, USA), phycoerythrin (PE)-cyanine 7 (Cy7)-conjugated anti-mouse CD8a (clone 53-6.7; BioLegend), allophycocyanin-conjugated antimouse CD45 (clone 30-F11; BioLegend), and PE D b /NP366-374 (ASNENMETM)-tetramer. After staining, the cells were fixed in BD FACS Lysing Solution (BD Pharmingen), the fixed samples were analyzed on a BD LSRFortessa cell analyzer (BD Biosciences, San Jose, CA, USA), and the counts were analyzed using BD FACSDiva (BD Biosciences) or FlowJo v10.2 (TreeStar Inc., Ashland, OR, USA) software.
Generation of HPV 16 pseudovirus
HPV 16 pseudoviruses were prepared by cotransfection of 293T cells with the pLucf (luciferase) marker plasmid together with p16L1/L2 plasmids. Cells were incubated at 37°C for 48 hr and then lysed by adding Triton X-100 (Sigma-Aldrich) at a final concentration of 0.5% in Dulbecco's PBS supplemented with 9.5 mM MgCl 2 . Lysates were digested with 0.2% Benzonase (SigmaAldrich) for 24 hr at 37°C to complete the virus maturation. Lysates were mixed with 0.8 M NaCl and clarified by centrifugation at 2000 Â g for 15 min. Pseudoviruses were purified on an OptiPrep density gradient medium (Sigma-Aldrich) by centrifugation at 234,000 Â g for 4 hr. After centrifugation, the fractions were collected and stored at À80°C.
Neutralization assay for HPV
Neutralization assay was carried out using a luciferaseexpressing HPV 16 pseudovirus system. Briefly, OptiPrep-purified luciferase-expressing HPV 16 pseudovirus sample was diluted 3000-fold and incubated on ice for 1 hr with a threefold serial dilution of mouse serum. 293T cells were infected by incubating with each pseudovirus-serum mixture for 3 days. The luciferase content in 10 mL clarified cell supernatant was measured using a Beetle-Juice kit (Takara, Shiga, Japan). The neutralization titer was defined as the reciprocal of the highest serum dilution that caused at least a 50% reduction in luciferase activity.
Splenocyte proliferation assay to measure effector T-lymphocyte responses against HPV vaccine
Isolated spleens were placed in serum-free (SF) RPMI 1640 (Hyclone) and processed through a 40-mm cell strainer (Corning) with 5 mL SF RPMI 1640. Following centrifugation, erythrocytes in the splenocyte fraction were removed by adding red blood lysis buffer (BD Biosciences). After washing and cell counting, 1 Â 10 6 splenocytes were seeded per well in a 48-well plate (Corning) with 5 mg/mL HPV vaccine for 3 days. After 3 days, the proliferation of splenocytes was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich), and concentrations of cytokines in the supernatant were measured by sandwich ELISA (eBioscience).
Quantitative RT-PCR
mRNA was extracted from the lungs of influenzainfected mice. For the cDNA template, a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) was used. To detect cDNA, the following real-time primers were used: influenza HA forward primer, 5 0 -GAC CRA TCC TGT CAC CTC TGA C-3 0 and reverse primer, 5 0 -AGG GCA TTY TGG ACA AAK CGT CTA-3 0 ; IFN-a forward primer, 5 0 -ATG GCT AGG CTC TGT GCT TTC CT-3 0 and reverse primer, 5 0 -GGG CTC TC AGA CTT CTG TG-3 0 ; and TNF-a forward primer, 5 0 -CCC AGA CC TCA CAC TCA GAT C-3 0 and reverse primer, 5 0 -GCC ACT CCA GCT GCT CCT C-3 0 . Quantitative RT-PCR was carried out using an iCycler MyiQ Single Color Real-time PCR Detection system (Bio-Rad, Hercules, CA, USA) and SYBR Premix Ex Taq II (Takara). Ct (threshold cycle) values were normalized by 18s mRNA.
Statistical analyses
Statistical analysis of the data was conducted using Excel 2013 software (Microsoft, Redmond, WA, USA). All data are expressed as the mean AE standard deviation (SD). Significant differences between means were identified using Student's t-test. Differences were considered significant at P < 0.05. (Fig. 1a) . Interestingly, the optical density of total IgG and IgG 1 reached 1.5 in the immunized WT mice, whereas that of the IgG 2a titer was <0.25 (Fig. 1a) . Moreover, the neutralization (PRNT) antibody and HI antibody titers were two and three times higher, respectively, in WT mice than in ASC À/À mice (Fig. 1b) .
RESULTS
Differences
Differences in CTL response between WT mice and ASC À/À mice after immunization with influenza vaccine not formulated with alum
To investigate the CTL response in immunized WT mice and ASC À/À mice, NP-specific CTL were measured in lung tissue 5 days after a live influenza virus challenge. Number of CTL, which are specific for influenza virus, was significantly higher in the vaccinated WT mice than in the unvaccinated WT mice (Fig. 2) . By contrast, ASC À/À mice did not show significant induction of a CTL response against influenza infection (Fig. 2) .
Analysis of the protective effect in immunized WT mice and ASC
À/À mice after influenza virus challenge
To investigate the protective effect in immunized WT mice and ASC À/À mice, the mice were infected with live influenza virus intranasally. At 5 days after the challenge, we analyzed weight loss and tissue injury, influenza HA titer, and proinflammatory cytokine levels in lung tissue. Immunized WT mice and ASC À/À mice both lost less weight than did the unvaccinated mice in both groups (about 79% and 86% in WT mice and 83% and 88% in ASC À/À mice, respectively, on 5 day after the challenge) (Fig. 3a) . In addition, the lungs in vaccinated WT mice showed less inflammation. The vaccinated WT mice showed clean bronchia and clear alveoli, whereas the vaccinated ASC À/À mice showed infiltration of immune cells and destroyed bronchia and alveoli (Fig. 3b) . mRNA of influenza virus was rarely detected in vaccinated WT lung samples. By contrast, the lung samples from vaccinated ASC À/À mice had higher mRNA levels of influenza virus than vaccinated WT mice (Fig. 3c) . Levels of mRNA for the proinflammatory cytokines TNF-a and IFN-a in lungs were lower after challenge in vaccinated mice than in unvaccinated mice (Fig. 3d) . Although the levels of mRNA for proinflammatory cytokines in lung tissue from unvaccinated ASC À/À mice were higher than those in lung tissue from vaccinated ASC À/ À mice, the levels in vaccinated ASC À/À mice were still higher than those in vaccinated WT mice (Fig. 3d) . This indicated that the influenza vaccine-induced immune response in ASC À/À mice may be inadequate to protect against viral challenge as effectively as that in WT mice.
Differences in humoral immune response between WT mice and ASC À/À mice after immunization with HPV vaccine formulated with or without alum
To investigate whether the inclusion of adjuvant could overcome the ASC deficiency effect in vaccination, we used the HPV vaccine, which is formulated with alum as an adjuvant. Immunization and bleeding schedule is shown in Supplementary Figure S2 . Interestingly, the total IgG antibody titer was similar in HPV-vaccinated WT and ASC À/À mice (Fig. 4a) . Moreover, the IgG 1 and IgG 2a antibody titers were also similar in WT and ASC À/ À mice after the second immunization. By contrast, after the third immunization, the titers of these antibodies were slightly lower in ASC À/À mice than in WT mice (Fig. 4a) . After the third immunization, neutralizing antibody titers in the final serum samples were similar in WT mice and ASC À/À mice (Fig. 4b) . In contrast, and as expected, the HPV vaccine without alum induced approximately threefold lower levels of HPV-specific antibodies, including IgG 1 and IgG 2a , in ASC À/À mice compared with those in WT mice (Fig. 4c) .
Differences in effector T-lymphocyte response between WT mice and ASC
À/À mice after immunization with HPV vaccine formulated with alum
To determine whether the effector T-lymphocyte response was induced in HPV-vaccinated ASC À/À mice, splenocytes from vaccinated mice were cultured with vaccine. Proliferation of splenocytes was measured using the MTT assay, and cytokine levels in the culture medium were measured by ELISA. Splenocyte proliferation was slightly greater in vaccinated WT mice than in vaccinated ASC À/À mice on day 5 of the splenocyte culture with the HPV vaccine (Fig. 5a ). Higher levels of IL-6 and IFN-g were secreted into the culture medium from splenocytes of vaccinated mice than from unvaccinated (control) mice (Fig. 5b) . A previous paper showed that the increase in splenocytes after antigen treatment reflects an increase in effector T cells in splenocytes (15) . In addition, IL-6 and IFN-g represent Th2 and Th1 cells, respectively (16) . Therefore, these data suggest that alum used as an adjuvant may affect Tcell proliferation after vaccination, even in the ASCdeficient condition.
DISCUSSION
Vaccine is one of the best tools for preventing disease. With increased understanding of the mechanisms underlying vaccination, the potential to use recombinant proteins to produce vaccines is receiving more attention (17, 18) . For example, HPV vaccines use the 'L1' protein, the major capsid protein of HPV, to trigger the immune response against HPV infection (19) . However, because recombinant proteins have low immunogenicity, vaccines must also include something else, such as an adjuvant, to initiate an effective immune response; there is much research on the use of adjuvants (19) . Alum increases antigen recognition by APC by forming a complex, which stimulates the inflammasome to induce a proinflammatory response and ultimately increase the immunogenicity of the vaccine (11). Our findings are consistent with the concept that alum-induced inflammasomes activate APC, and these activated cells contribute to increasing the vaccine's efficacy through their interaction with other immune cells (11) . In our study, we explored the role of ASC, which is an adaptor protein of inflammasomes, in vaccination by using ASC À/À mice. In addition, we used two types of vaccine, the HPV vaccine with alum and the influenza vaccine without alum, to analyze the effect of host factors in alum-induced immune responses. Although these vaccines target different viruses (i.e. influenza and HPV), the principles behind their induction of immune responses are similar. Although they have different production methods, with influenza vaccine being a chemically inactivated vaccine and the HPV vaccine being a self-assembled virus-like particle without a viral genome (19, 20) , they are both essentially exogenous proteins and therefore usually trigger a humoral immune response, not a cell-mediated immune response. Thus, we consider that use of both vaccines allows evaluation of the role of host factors in the effect of alum.
Antibody titers were lower in ASC À/À mice than in WT mice after immunization with an influenza vaccine without adjuvant. Unvaccinated ASC À/À mice had higher immunoglobulin titers than did WT mice ( Supplementary Fig. S3 ). This suggests that ASC À/À mice produced more nonspecific IgG and less antigenspecific IgG after vaccination. Inflammasome activation affects immune stimulation and balance after pathogen infection and vaccination (21) (22) (23) . However, the high titers of nonspecific Ig before immunization in ASC À/À mice may disturb the production of vaccine-induced specific Ig. ASC À/À mice showed an insufficient CTL response after viral challenge. This suggests that the low antibody titer and CTL response may reflect insufficient protection after viral challenge, and that ASC may play a role in determining the efficacy of the humoral and cellular immune responses after vaccination.
By contrast, the HPV vaccine, which was formulated with alum, overcame the effects of ASC deficiency that appeared in response to the influenza vaccine. Although the final antibody titers were slightly lower in ASC À/À mice than in WT mice after the third vaccination, the antibody titers, including total IgG, IgG 1 , and IgG 2a , as well as neutralizing antibodies, after the second booster did not differ significantly between WT and ASC À/À mice. Moreover, effector T-cell proliferation after vaccination did not differ much between WT and ASC À/À mice. However, the HPV vaccine without alum could not overcome the effects of ASC deficiency, such as poor induction of HPVspecific antibodies. These results suggest that the vaccine with the alum induced both Th1 and Th2 responses to the same extent in ASC À/À as in WT mice. We propose that the humoral and cellular immune responses triggered by alum may act through another route in addition to the inflammasome pathway.
Taken together, our findings suggest that ASC, as a component of inflammasomes, is important in inducing the vaccine-stimulated immune response, and that alum as an adjuvant may induce an immune response without activating inflammasomes. Previous papers have reported that the effects of alum on vaccination are dependent on the inflammasome pathway (24, 25) . However, a recent paper showed that alum could stimulate an inflammatory response independently of inflammasome activation (26) . This previous paper and our data suggest that alum can stimulate a vaccineinduced immune response through both inflammasomedependent and Àindependent pathways. Further studies are needed to identify the precise mechanism responsible for the effects of alum on the inflammasome-independent pathway, and to confirm the effectiveness of using vaccine strategies that include alum.
SUPPORTING INFORMATION
Additional supporting information may be found in the online version of this article at the publisher's website. Fig. S1 . Mice were immunized with the influenza virus vaccine twice at 2-week intervals, and serum was collected from the facial vein on days 10 and 28 after the first vaccination. All mice were infected with 5.5 Â 104 pfu influenza virus (A/H1N1/California/04/ 09) 7 weeks after the first vaccination. The mice were killed on day 5 after influenza virus infection. Fig. S2 . Mice were immunized with the HPV vaccine three times at 2-week intervals, and serum was collected from the facial vein on days 10, 24, and 49 after the first vaccination. The mice were killed on day 49 after the first vaccination.gr7 Fig. S3 . IgG titer was measured in serum samples using a Mouse Total IgG Kit (n ¼ 3, pooled samples from five individual samples). Data are expressed as mean AE SD (n ¼ 3).
ÃÃ P < 0.01.
